Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Estudo para Avaliar a Segurança e Eficácia a Longo Prazo do Rozanolixizumab em Participantes Adultos com Miastenia Gravis Ocular (MyVisionXT)

5 de novembro de 2026 atualizado por: UCB Biopharma SRL

Um Estudo de Extensão de Fase 3, Aberto, para Avaliar a Segurança e Eficácia a Longo Prazo do Rozanolixizumab em Participantes Adultos com Miastenia Gravis Ocular

The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.

Visão geral do estudo

Status

Recrutamento

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

100

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: UCB Cares
  • Número de telefone: 00184459922733 (UCB)
  • E-mail: ucbcares@ucb.com

Locais de estudo

      • Beijing, China
        • Recrutamento
        • Mg0039 31901
      • Beijing, China
        • Recrutamento
        • Mg0039 31912
      • Chongqing, China
        • Recrutamento
        • Mg0039 31908
      • Nanchang, China
        • Recrutamento
        • Mg0039 31907
      • Suzhou, China
        • Recrutamento
        • Mg0039 31902
      • Barcelona, Espanha
        • Recrutamento
        • Mg0039 20604
      • Madrid, Espanha
        • Recrutamento
        • Mg0039 20611
      • Murcia, Espanha
        • Recrutamento
        • Mg0039 20602
      • Málaga, Espanha
        • Recrutamento
        • Mg0039 20606
    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85251
        • Recrutamento
        • Mg0039 10104
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • Mg0039 10103
      • Nice, França
        • Recrutamento
        • Mg0039 20301
      • Sarajishvili, Geórgia
        • Recrutamento
        • Mg0039 21403
      • Tbilisi, Geórgia
        • Recrutamento
        • Mg0039 21402
      • Kobe, Japão
        • Recrutamento
        • Mg0039 31802
      • Minatoku, Japão
        • Recrutamento
        • Mg0039 31804
      • Sendai, Japão
        • Recrutamento
        • Mg0039 31805
      • Lublin, Polônia
        • Recrutamento
        • Mg0039 21206

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Participant must be a minimum of 18 years of age inclusive at the time of signing the informed consent form (ICF)

  • Participant must have received at least 1 dose of investigational medicinal product (IMP) (rozanolixizumab or placebo) in MG0038

  • Participant for whom the investigator considers a favorable benefit/risk for participation

  • Participant who, alone or with assistance of the caregiver, is considered reliable and capable of adhering to the protocol visit schedule or medication intake according to the judgement of the investigator

  • Male or female

  • A female participant is eligible to participate if she is not, not breastfeeding (including pumping breastmilk to feed a child), and at least 1 of the following conditions applies:

    • Not a woman of childbearing potential (WOCBP) OR
    • A WOCBP who agrees to follow the contraceptive guidance for the entire study period
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol

Exclusion Criteria:

  • Participant meets any of the withdrawal criteria defined in MG0038
  • Participant has a clinically relevant active infection (resulting in hospitalization or requiring intravenous (IV) antibiotic treatment) within 6 weeks before study entry.
  • Participant intends to have a live vaccination during the study or within 8 weeks following the final dose of rozanolixizumab
  • Participant has been administered with the prohibited immunosuppressive medications, biologics, or other therapies
  • Participant has planned use of prohibited medications

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Rozanolixizumab

The study is composed of Extended Observation Period(s) and Symptom-driven Cycle(s). Based on their clinical need for treatment, study participants will be able to start the study with either an Extended Observation Period or a Symptom-driven Cycle.

A Symptom-driven Cycle will be initiated based on disease worsening and participants will receive rozanolixizumab based on investigator's medical judgement.

Rozanolixizumab will be administered by subcutaneous infusion.

Outros nomes:
  • UCB7665

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of treatment-emergent adverse events (TEAEs)
Prazo: Up to 2 years

Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment.

Up to 2 years
Incidence of treatment-emergent serious adverse events (TESAEs)
Prazo: Up to 2 years

An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed:

  • Results in death
  • Is life-threatening
  • Requires inpatient hospitalization or prolongation of existing hospitalization
  • Results in persistent or significant disability/incapacity
  • Is a congenital anomaly/birth defect
  • Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.
Up to 2 years
Incidence of TEAEs leading to permanent withdrawal of study treatment
Prazo: Up to 2 years

Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment. This measure considers any TEAE leading to permanent withdrawal from study.

Up to 2 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome part)
Prazo: At Day 43 (of the first 3 Symptom-driven Cycles)

MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week".

At Day 43 (of the first 3 Symptom-driven Cycles)
Change from Baseline at Day 43 in Myasthenia Gravis Activities of Daily Living (MG-ADL) ocular score
Prazo: At Day 43 (of the first 3 Symptom-driven Cycles)

The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability. The two ocular items will be summed for the ocular score, ranging from 0 to 6.

At Day 43 (of the first 3 Symptom-driven Cycles)
Change from Baseline at Day 43 in Myasthenia Gravis Symptoms Patient-Reported Outcome (MGSPRO) ocular muscle weakness scale score
Prazo: At Day 43 (of the first 3 Symptom-driven Cycles)

The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Only the ocular muscle weakness scale will be used in this study. Ocular symptom severity is assessed over the past 7 days using a 4-point verbal rating scale (none, mild, moderate, severe)

At Day 43 (of the first 3 Symptom-driven Cycles)
Change from Baseline at Day 43 in Myasthenia Gravis Quality of Life 15-item Scale (revised version) (MG-QoL15r) total score
Prazo: At Day 43 (of the first 3 Symptom-driven Cycles)

The MG-QoL15r is a 15-item PRO measure that is designed to assess aspects of health-related quality of life related to MG. The recall period that will be used is "past 7 days". Each item has 3 response options (0-2) and the total score ranges from 0 to 30, with higher scores indicating more severe impact on health-related QoL (HRQOL).

At Day 43 (of the first 3 Symptom-driven Cycles)
Study participant who generalizes to Myasthenia Gravis Foundation of America (MGFA) class ≥2 over time
Prazo: Up to 2 years

MGFA Clinical Classification is a 5-stage classification (I to V), with a higher class indicating more severe disease.

Up to 2 years
Change from Baseline in MGII total and generalized score over time
Prazo: Up to 2 years

MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week".

Up to 2 years
Change from Baseline in MG-ADL total score over time
Prazo: Up to 2 years

The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability. The two ocular items will be summed for the ocular score, ranging from 0 to 6.

Up to 2 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

16 de setembro de 2026

Conclusão Primária (Estimado)

17 de março de 2031

Conclusão do estudo (Estimado)

17 de março de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

6 de março de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de março de 2026

Primeira postagem (Real)

11 de março de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • MG0039
  • 2025-524757-14-00 (Ctis)
  • U1111-1334-3218 (Outro identificador: Universal Trial Number)
  • CTR20262521 (Identificador de registro: ChinaDrugTrials.org.cn)
  • 2025 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Prazo de Compartilhamento de IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Critérios de acesso de compartilhamento IPD

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever